Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, January 10th. The brokerage currently has a $105.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s price target points to a potential downside of 26.61% from the stock’s previous close.
According to Zacks, “Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-ß agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-ß agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania. “
Several other brokerages have also recently weighed in on MDGL. Evercore ISI initiated coverage on shares of Madrigal Pharmaceuticals in a research note on Friday, September 22nd. They issued an “outperform” rating and a $65.00 price objective for the company. Roth Capital raised their target price on shares of Madrigal Pharmaceuticals from $82.00 to $170.00 and gave the company a “buy” rating in a report on Monday, December 11th. HC Wainwright assumed coverage on shares of Madrigal Pharmaceuticals in a report on Wednesday, November 29th. They set a “buy” rating and a $54.00 price target on the stock. Finally, JMP Securities lifted their price target on shares of Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an “outperform” rating in a report on Friday, October 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $139.20.
Madrigal Pharmaceuticals (NASDAQ:MDGL) opened at $143.07 on Wednesday. Madrigal Pharmaceuticals has a 12-month low of $13.09 and a 12-month high of $152.62.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.11. equities research analysts expect that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. purchased a new stake in Madrigal Pharmaceuticals in the third quarter valued at approximately $325,000. Bank of New York Mellon Corp raised its stake in Madrigal Pharmaceuticals by 17.9% in the third quarter. Bank of New York Mellon Corp now owns 12,945 shares of the biopharmaceutical company’s stock valued at $582,000 after purchasing an additional 1,963 shares in the last quarter. VHCP Management II LLC purchased a new stake in Madrigal Pharmaceuticals in the third quarter valued at approximately $1,349,000. Northern Trust Corp grew its position in Madrigal Pharmaceuticals by 151.2% during the second quarter. Northern Trust Corp now owns 50,069 shares of the biopharmaceutical company’s stock valued at $814,000 after acquiring an additional 30,134 shares during the last quarter. Finally, Victory Capital Management Inc. bought a new position in Madrigal Pharmaceuticals during the third quarter valued at approximately $2,274,000. 20.53% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Madrigal Pharmaceuticals (MDGL) Rating Increased to Buy at Zacks Investment Research” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/02/06/madrigal-pharmaceuticals-mdgl-upgraded-at-zacks-investment-research.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.